Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

Inclusion Criteria: * Patients must have a diagnosis of CLL; * No prior or no standard treatment for CLL; * Binet stage B, C or symptomatic stage A; * Needs treatment to control diseases; * (Eastern Cooperative Oncology Group)ECOG performance status ≤ 2 * Life expectancy ≥3 months * Written informed consent Exclusion Criteria: * Patients were diagnosed with or treated for malignant tumors other than CLL (including active central nervous system lymphoma) within one year prior to entering the study * Transformation to Richter's syndrome, or prolymphocytic leukemia(PLL) * Autoimmune hemolytic anemia requiring glucocorticoid therapy * Autoimmune thrombocytopenia requiring glucocorticoid therapy * Alanine aminotransferase(ALT)\>3 times upper limits of normal value, Aspartate aminotransferase(AST)\>3 times upper limits of normal value, Total bilirubin(TBIL)\>2 times upper limits of normal value, serum creatinine\>1.5 times upper limits of normal value; * Other serious Concomitant diseases which affect participation of this study(uncontrolled diabetes, gastric ulcer, cardiac and pulmonary diseases, at active phases of autoimmune diseases; * Serious or uncontrolled infections; * Central nervous system dysfunction with clinical symptoms; * Patients received major surgery within 30 days prior to study entry; * Pregnant or lactating women * Allergic to study drug or mannitol * Participation in any other clinical trials within 3 months prior to study entry